Entasis Therapeutics Holdings Inc.

If you purchased Entasis Therapeutics Holdings Inc. securities and would like to join the action, please click "Join This Action" below.

ETTX STOCK ALERT: HALPER SADEH LLP IS INVESTIGATING WHETHER THE SALE OF ENTASIS THERAPEUTICS HOLDINGS INC. IS FAIR TO SHAREHOLDERS

May 23, 2022.

New York, New York—Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX) to Innoviva, Inc. for $2.20 per share in cash is fair to Entasis shareholders.

The investigation concerns whether Entasis and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Entasis shareholders; (2) determine whether Innoviva is underpaying for Entasis; and (3) disclose all material information necessary for Entasis shareholders to adequately assess and value the merger consideration. On behalf of Entasis shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.

Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Scroll to Top